Loading clinical trials...
Loading clinical trials...
The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
VAMC
Denver, Colorado, United States
Start Date
June 1, 1998
Completion Date
June 1, 2003
Last Updated
January 21, 2009
ondansetron
DRUG
neuropsychological testing
BEHAVIORAL
nicotine
DRUG
haloperidol
DRUG
Lead Sponsor
US Department of Veterans Affairs
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions